Repare Therapeutics Inc (NAS:RPTX)

$ 3.12 0.02 (0.65%) Market Cap: 132.43 Mil Enterprise Value: -101.79 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 44/100

Repare Therapeutics Inc To Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Call Transcript
Oct 13, 2023

Repare Therapeutics Inc To Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Call Transcript

Oct 13, 2023 / 09:30PM GMT

Release Date Price: $5.28 (-5.71%)

Transcript

Operator

Thank you for standing by. This is the webcast operator. Welcome to the Repare Therapeutics Investor Update focused on its Lunresertib MYTHIC clinical trial. Please note that this webcast is being recorded. (Operator Instructions)

I would now like to turn the webcast over to Steve Forte, Executive Vice President and Chief Financial Officer. Steve, Please go ahead.

Steve Forte

Repare Therapeutics Inc. - Executive VP & CFO

Good evening and thank you for joining us today to discuss the positive initial data from our MYTHIC Clinical Trial. Before we begin, I invite you to visit the Investors section of our website to view the webcast slides and today's press release on our ongoing MYTHIC Trial. Today's presentation will begin with introductory comments by our President and CEO, Lloyd Segal. We are pleased to welcome Dr. Timothy Yap of the University of Texas, MD Anderson Cancer Center, the principal investigator on the MYTHIC Trial, who will review data presented earlier today at ENA, highlighting initial data from our ongoing MYTHIC Clinical Trial.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.